GlaxoSmithKline reported 244.7B in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alcon AG ALC:SW 552.89M 13.11M
Amgen AMGN:US $ 3004M 337M
AstraZeneca AZN:LN 292568.43M 24571.33M
Bayer BAYN:GR € 4762M 490M
Biogen BIIB:US $ 1075.7M 401M
Bristol Myers Squibb BMY:US $ 5780M 8M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
Fresenius FRE:GR € 1381M 115M
Fresenius Medical Care FME:GR € 744M 108.14M
Galapagos GLPG:NA € -43.87M 28.24M
Gilead Sciences GILD:US $ 2585M 837M
GlaxoSmithKline GSK:LN 244700M 1400M
Glaxosmithkline GSK:US $ 2447M 673M
Hikma Pharmaceutical HIK:LN 349M 19M
Lonza Group LONN:SW 956M 167M
Merck MRK:GR € 1791M 161M
Novartis NOVN:VX SF 4660M 108M
Orion ORNBV:FH € 83.1M 0.1M
Pfizer PFE:US $ 12921M 1739M
Philips PHIA:NA € 476M 122M
Recordati REC:IM € 155M 8.05M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M